STOK News and Press, Stoke Therapeutics Inc.

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– Stoke Therap...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment ...

–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life to be evaluated as secondary objectives– –ADOA is the most common inherited...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment ...

Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA PR Newswire New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion o...

2026-01-15 08:49:10 ET ... Read the full article on Seeking Alpha For further details see: Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity

2026-01-12 10:11:57 ET More on Stoke Therapeutics Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating Seeking Alpha’s Quant Rating on Stoke Therapeutics Historical earnings data for Stoke Therapeutics Financial information ...

— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in first half 2027— — Discussions with FDA ongoing following recent multidisciplinary meeting; Company continue...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatmen...

2026-01-05 07:05:47 ET from Canaccord Genuity issued a price target of $36.00 for STOK on 2026-01-05 11:53:37. The adjusted price target was set to $36.00. At the time of the announcement, STOK was trading at $30.9. The overall price target consensus is at $37.67 with hi...